Fig. 1: NK-92/5.28.z cell mediated lysis of HER2-positive GB cells.
From: CAR-NK cell therapy combined with checkpoint inhibition induces an NKT cell response in glioblastoma
a Expression of human HER2 in the GL261 glioma cell line; (left) flow cytometric analysis, (right) Western blot. b Specific lysis of NK-92/5.28.z cells compared to NK-92 wildtype (WT) cells targeted against GL261/HER2 cells (n = 3; one-tailed Student’s t test. ***p < 0.001). c IHC staining for PD-L1 in glioblastoma relapse tissue from a patient participating in the CAR2BRAIN trial. d In vitro induction of PD-L1 on GL261/HER2 cells upon stimulation in a co-culture assay measured via flow cytometry (n = 3, mean ± SEM; ANOVA with Sidák’s multiple comparison test. **p < 0.01). e Induction of PD-1 expression on ex vivo isolated CD3, CD4 and CD8 T cells upon stimulation in a co-culture assay measured via flow cytometry (n = 3, mean ± SEM; ANOVA with Sidák’s multiple comparison test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p-value < 0.0001). f In vitro secretion of pro-inflammatory cytokines of isolated murine splenocytes upon stimulation in a co-culture assay measured via flow cytometry (n = 10, scatter dot blot and median expression; ANOVA with Sidák’s multiple comparison test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
